Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Carcinoma, Non-Small-Cell Lung | 117 | 2024 | 5426 | 10.310 |
Why?
|
Lung Neoplasms | 148 | 2024 | 13589 | 7.960 |
Why?
|
Proto-Oncogene Proteins c-ret | 19 | 2024 | 228 | 4.340 |
Why?
|
Receptor Protein-Tyrosine Kinases | 26 | 2022 | 1628 | 3.400 |
Why?
|
Pyrazoles | 33 | 2024 | 2024 | 2.680 |
Why?
|
Protein Kinase Inhibitors | 47 | 2024 | 5709 | 2.650 |
Why?
|
Drug Resistance, Neoplasm | 31 | 2024 | 5342 | 2.170 |
Why?
|
Carbazoles | 7 | 2021 | 221 | 1.930 |
Why?
|
Pyridines | 26 | 2024 | 2888 | 1.900 |
Why?
|
Pyrimidines | 19 | 2024 | 3050 | 1.710 |
Why?
|
Piperidines | 11 | 2024 | 1664 | 1.640 |
Why?
|
Lactams, Macrocyclic | 13 | 2022 | 318 | 1.520 |
Why?
|
Lactams | 12 | 2022 | 158 | 1.360 |
Why?
|
Antineoplastic Agents | 27 | 2024 | 13709 | 1.270 |
Why?
|
Protein-Tyrosine Kinases | 9 | 2021 | 2433 | 1.230 |
Why?
|
Mutation | 55 | 2024 | 30235 | 1.130 |
Why?
|
Aminopyridines | 13 | 2022 | 578 | 1.120 |
Why?
|
Immunotherapy | 16 | 2024 | 4728 | 1.050 |
Why?
|
Oncogene Proteins, Fusion | 8 | 2022 | 1614 | 1.040 |
Why?
|
Gene Rearrangement | 10 | 2020 | 1139 | 1.040 |
Why?
|
Proto-Oncogene Proteins | 9 | 2021 | 4534 | 1.020 |
Why?
|
Acrylamides | 3 | 2024 | 260 | 0.950 |
Why?
|
Neoplasms | 27 | 2024 | 22389 | 0.920 |
Why?
|
Molecular Targeted Therapy | 11 | 2023 | 2834 | 0.850 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 12 | 2023 | 1766 | 0.830 |
Why?
|
Sulfones | 7 | 2018 | 448 | 0.800 |
Why?
|
Brain Neoplasms | 16 | 2022 | 9177 | 0.770 |
Why?
|
Aniline Compounds | 4 | 2024 | 1094 | 0.750 |
Why?
|
Proto-Oncogene Proteins c-met | 5 | 2021 | 568 | 0.750 |
Why?
|
Thoracic Neoplasms | 1 | 2023 | 270 | 0.710 |
Why?
|
Phospholipase D | 1 | 2019 | 67 | 0.670 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 21 | 2024 | 11844 | 0.660 |
Why?
|
Drug Discovery | 2 | 2019 | 1062 | 0.660 |
Why?
|
Humans | 190 | 2024 | 768369 | 0.650 |
Why?
|
Antigens, Neoplasm | 2 | 2024 | 2003 | 0.650 |
Why?
|
Gene Fusion | 1 | 2021 | 356 | 0.610 |
Why?
|
Carcinoma, Large Cell | 1 | 2018 | 114 | 0.600 |
Why?
|
Translocation, Genetic | 5 | 2016 | 1395 | 0.600 |
Why?
|
Anilides | 3 | 2024 | 415 | 0.570 |
Why?
|
Antibodies, Monoclonal | 9 | 2024 | 9261 | 0.560 |
Why?
|
Pyridazines | 2 | 2016 | 204 | 0.550 |
Why?
|
Imidazoles | 4 | 2021 | 1174 | 0.550 |
Why?
|
Indoles | 1 | 2024 | 1834 | 0.500 |
Why?
|
Gene Amplification | 2 | 2020 | 1091 | 0.500 |
Why?
|
Quinazolines | 2 | 2018 | 1376 | 0.480 |
Why?
|
Lung Diseases, Interstitial | 1 | 2023 | 935 | 0.470 |
Why?
|
Adenocarcinoma | 10 | 2021 | 6400 | 0.440 |
Why?
|
Meningeal Carcinomatosis | 1 | 2013 | 63 | 0.430 |
Why?
|
Aged | 66 | 2024 | 171514 | 0.420 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 7 | 2024 | 1104 | 0.420 |
Why?
|
Middle Aged | 69 | 2024 | 223406 | 0.410 |
Why?
|
Pneumonia | 1 | 2023 | 2162 | 0.380 |
Why?
|
ras Proteins | 2 | 2014 | 1058 | 0.370 |
Why?
|
Aged, 80 and over | 37 | 2024 | 59679 | 0.370 |
Why?
|
Melanoma | 4 | 2024 | 5740 | 0.360 |
Why?
|
Carcinoma, Squamous Cell | 5 | 2021 | 4083 | 0.350 |
Why?
|
Carcinoma, Neuroendocrine | 3 | 2024 | 342 | 0.340 |
Why?
|
Prognosis | 22 | 2022 | 30031 | 0.330 |
Why?
|
Male | 70 | 2024 | 364761 | 0.330 |
Why?
|
Female | 79 | 2024 | 396926 | 0.320 |
Why?
|
Adult | 53 | 2024 | 223528 | 0.320 |
Why?
|
Tumor Microenvironment | 9 | 2024 | 3939 | 0.300 |
Why?
|
Combined Modality Therapy | 3 | 2019 | 8559 | 0.290 |
Why?
|
Spinal Neoplasms | 1 | 2013 | 715 | 0.280 |
Why?
|
Cell Line, Tumor | 15 | 2024 | 17149 | 0.270 |
Why?
|
Meningeal Neoplasms | 1 | 2015 | 1251 | 0.250 |
Why?
|
Survival Analysis | 7 | 2021 | 10127 | 0.240 |
Why?
|
Neoplasm Staging | 11 | 2021 | 11249 | 0.240 |
Why?
|
Acetonitriles | 2 | 2022 | 55 | 0.240 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 2 | 2018 | 639 | 0.230 |
Why?
|
Retrospective Studies | 30 | 2023 | 81835 | 0.230 |
Why?
|
Biopsy | 5 | 2021 | 6816 | 0.230 |
Why?
|
Treatment Outcome | 21 | 2021 | 65408 | 0.220 |
Why?
|
Clinical Trials as Topic | 5 | 2021 | 8051 | 0.220 |
Why?
|
Cystatin C | 1 | 2024 | 272 | 0.210 |
Why?
|
T-Lymphocytes | 5 | 2024 | 10269 | 0.200 |
Why?
|
Early Detection of Cancer | 3 | 2022 | 3230 | 0.200 |
Why?
|
Chylous Ascites | 1 | 2022 | 21 | 0.200 |
Why?
|
Taxoids | 2 | 2016 | 669 | 0.200 |
Why?
|
Platinum | 2 | 2024 | 222 | 0.200 |
Why?
|
Pneumonectomy | 2 | 2020 | 1159 | 0.200 |
Why?
|
Myocarditis | 2 | 2024 | 804 | 0.200 |
Why?
|
Blood | 1 | 2024 | 597 | 0.200 |
Why?
|
Chylothorax | 1 | 2022 | 83 | 0.190 |
Why?
|
Cytidine Deaminase | 1 | 2023 | 243 | 0.190 |
Why?
|
Triazines | 2 | 2021 | 312 | 0.190 |
Why?
|
Aging | 2 | 2022 | 8762 | 0.180 |
Why?
|
Neoadjuvant Therapy | 2 | 2024 | 2896 | 0.180 |
Why?
|
Medical Oncology | 3 | 2024 | 2347 | 0.180 |
Why?
|
Lung | 5 | 2023 | 10090 | 0.180 |
Why?
|
Survival Rate | 10 | 2021 | 12875 | 0.180 |
Why?
|
Antigens, Differentiation, B-Lymphocyte | 1 | 2021 | 317 | 0.180 |
Why?
|
Piperazines | 5 | 2022 | 2546 | 0.170 |
Why?
|
Neuroendocrine Cells | 1 | 2021 | 62 | 0.170 |
Why?
|
Thyroid Neoplasms | 3 | 2024 | 2360 | 0.170 |
Why?
|
Karnofsky Performance Status | 1 | 2020 | 167 | 0.170 |
Why?
|
Antigens, CD | 2 | 2021 | 4022 | 0.170 |
Why?
|
Benzamides | 3 | 2021 | 1381 | 0.170 |
Why?
|
Neoplasm Recurrence, Local | 6 | 2022 | 9425 | 0.160 |
Why?
|
Amino Acid Substitution | 2 | 2021 | 1742 | 0.160 |
Why?
|
Gene Order | 1 | 2019 | 169 | 0.160 |
Why?
|
Physician-Patient Relations | 1 | 2012 | 3267 | 0.160 |
Why?
|
Neoplasm, Residual | 1 | 2024 | 1014 | 0.160 |
Why?
|
Sarcopenia | 1 | 2024 | 376 | 0.160 |
Why?
|
Resorcinols | 1 | 2018 | 41 | 0.160 |
Why?
|
Bone Neoplasms | 2 | 2022 | 2562 | 0.150 |
Why?
|
Polymyalgia Rheumatica | 1 | 2018 | 52 | 0.150 |
Why?
|
Tomography, X-Ray Computed | 10 | 2024 | 20763 | 0.150 |
Why?
|
Creatinine | 1 | 2024 | 1915 | 0.150 |
Why?
|
Software | 1 | 2012 | 4465 | 0.150 |
Why?
|
HSP90 Heat-Shock Proteins | 2 | 2018 | 423 | 0.150 |
Why?
|
Cyclin-Dependent Kinase 6 | 1 | 2021 | 352 | 0.150 |
Why?
|
Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2018 | 117 | 0.150 |
Why?
|
Viral Load | 2 | 2024 | 3374 | 0.140 |
Why?
|
Structure-Activity Relationship | 2 | 2021 | 3074 | 0.140 |
Why?
|
Budgets | 1 | 2019 | 232 | 0.140 |
Why?
|
Organophosphorus Compounds | 1 | 2018 | 207 | 0.140 |
Why?
|
Patient Simulation | 1 | 2019 | 297 | 0.140 |
Why?
|
Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 2018 | 224 | 0.140 |
Why?
|
In Situ Hybridization, Fluorescence | 2 | 2013 | 2525 | 0.140 |
Why?
|
Isoxazoles | 1 | 2018 | 233 | 0.140 |
Why?
|
Patient Selection | 5 | 2021 | 4266 | 0.140 |
Why?
|
Histocompatibility Antigens Class II | 1 | 2021 | 1438 | 0.140 |
Why?
|
Quinazolinones | 1 | 2018 | 222 | 0.130 |
Why?
|
Exons | 3 | 2018 | 2392 | 0.130 |
Why?
|
Receptors, Antigen, T-Cell | 2 | 2024 | 2564 | 0.130 |
Why?
|
Small Cell Lung Carcinoma | 1 | 2021 | 451 | 0.130 |
Why?
|
Eligibility Determination | 1 | 2020 | 420 | 0.130 |
Why?
|
Genes, erbB-1 | 1 | 2017 | 163 | 0.130 |
Why?
|
Tyrosine | 1 | 2020 | 1428 | 0.130 |
Why?
|
Young Adult | 16 | 2022 | 60038 | 0.130 |
Why?
|
Mutagenesis, Insertional | 1 | 2018 | 662 | 0.130 |
Why?
|
Arthritis, Psoriatic | 1 | 2018 | 220 | 0.130 |
Why?
|
Disease-Free Survival | 5 | 2018 | 6856 | 0.120 |
Why?
|
Glomerular Filtration Rate | 1 | 2024 | 2226 | 0.120 |
Why?
|
Antibodies, Neutralizing | 2 | 2023 | 2005 | 0.120 |
Why?
|
Cranial Irradiation | 1 | 2018 | 395 | 0.120 |
Why?
|
Follow-Up Studies | 11 | 2021 | 39429 | 0.120 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2016 | 259 | 0.120 |
Why?
|
Transforming Growth Factor beta | 1 | 2023 | 2003 | 0.120 |
Why?
|
Oncogenes | 1 | 2020 | 1235 | 0.120 |
Why?
|
Endpoint Determination | 2 | 2014 | 590 | 0.120 |
Why?
|
Radiation-Sensitizing Agents | 1 | 2016 | 350 | 0.120 |
Why?
|
Xenograft Model Antitumor Assays | 6 | 2018 | 3619 | 0.120 |
Why?
|
Carboplatin | 3 | 2024 | 798 | 0.120 |
Why?
|
Adiposity | 1 | 2024 | 1888 | 0.110 |
Why?
|
Drug Design | 1 | 2019 | 1050 | 0.110 |
Why?
|
Pregnancy Complications, Neoplastic | 1 | 2016 | 259 | 0.110 |
Why?
|
Precancerous Conditions | 1 | 2021 | 988 | 0.110 |
Why?
|
Drug Administration Schedule | 3 | 2019 | 4861 | 0.110 |
Why?
|
Drug Costs | 2 | 2019 | 1196 | 0.110 |
Why?
|
Gene Knockout Techniques | 1 | 2017 | 808 | 0.110 |
Why?
|
Antibodies, Viral | 2 | 2023 | 3210 | 0.110 |
Why?
|
Pyrimidinones | 1 | 2016 | 387 | 0.110 |
Why?
|
Lymphocytes | 1 | 2021 | 2611 | 0.110 |
Why?
|
Puerperal Disorders | 1 | 2016 | 303 | 0.110 |
Why?
|
Maximum Tolerated Dose | 3 | 2021 | 890 | 0.110 |
Why?
|
Skin Neoplasms | 3 | 2024 | 5891 | 0.110 |
Why?
|
DNA Mutational Analysis | 3 | 2016 | 4120 | 0.100 |
Why?
|
Models, Molecular | 2 | 2021 | 5441 | 0.100 |
Why?
|
Dyspnea | 1 | 2021 | 1352 | 0.100 |
Why?
|
Genotype | 4 | 2016 | 13045 | 0.100 |
Why?
|
Blood-Brain Barrier | 1 | 2019 | 1034 | 0.100 |
Why?
|
CD4-Positive T-Lymphocytes | 2 | 2022 | 4403 | 0.100 |
Why?
|
Alleles | 2 | 2021 | 6880 | 0.100 |
Why?
|
Vaccination | 2 | 2024 | 3433 | 0.100 |
Why?
|
Skin Diseases | 1 | 2021 | 1099 | 0.100 |
Why?
|
Models, Theoretical | 1 | 2024 | 3590 | 0.100 |
Why?
|
Drug Delivery Systems | 1 | 2023 | 2238 | 0.100 |
Why?
|
Immunohistochemistry | 3 | 2016 | 11139 | 0.100 |
Why?
|
Single-Cell Analysis | 2 | 2024 | 2531 | 0.100 |
Why?
|
Prospective Studies | 9 | 2022 | 54913 | 0.100 |
Why?
|
Cross Infection | 1 | 2021 | 1425 | 0.100 |
Why?
|
High-Throughput Nucleotide Sequencing | 3 | 2020 | 3669 | 0.100 |
Why?
|
Immunotherapy, Adoptive | 1 | 2022 | 1505 | 0.100 |
Why?
|
Myocardium | 1 | 2024 | 4789 | 0.100 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2024 | 10358 | 0.090 |
Why?
|
Receptor, erbB-2 | 1 | 2022 | 2586 | 0.090 |
Why?
|
Sarcoma | 1 | 2022 | 1806 | 0.090 |
Why?
|
Disease Progression | 7 | 2024 | 13643 | 0.090 |
Why?
|
CD8-Positive T-Lymphocytes | 5 | 2024 | 4613 | 0.090 |
Why?
|
Pyridones | 1 | 2016 | 819 | 0.090 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2021 | 3520 | 0.090 |
Why?
|
Genomics | 2 | 2023 | 5912 | 0.090 |
Why?
|
Neoplasm Metastasis | 4 | 2022 | 4931 | 0.090 |
Why?
|
Mitral Valve | 1 | 2018 | 1473 | 0.090 |
Why?
|
Serine Endopeptidases | 1 | 2015 | 1032 | 0.090 |
Why?
|
Microtubule-Associated Proteins | 1 | 2015 | 1078 | 0.090 |
Why?
|
Mice | 14 | 2024 | 82051 | 0.090 |
Why?
|
Paclitaxel | 3 | 2024 | 1737 | 0.090 |
Why?
|
Apoptosis | 4 | 2019 | 9526 | 0.080 |
Why?
|
Neoplasm Proteins | 1 | 2022 | 3611 | 0.080 |
Why?
|
NF-E2-Related Factor 2 | 2 | 2023 | 380 | 0.080 |
Why?
|
Neutrophils | 1 | 2021 | 3790 | 0.080 |
Why?
|
Cell Proliferation | 4 | 2017 | 10490 | 0.080 |
Why?
|
Cytokines | 1 | 2023 | 7440 | 0.080 |
Why?
|
Radiosurgery | 1 | 2018 | 1354 | 0.080 |
Why?
|
Animals | 18 | 2024 | 169424 | 0.070 |
Why?
|
Streptococcal Infections | 1 | 2012 | 619 | 0.070 |
Why?
|
Time Factors | 5 | 2021 | 40271 | 0.070 |
Why?
|
Cell Survival | 2 | 2016 | 5800 | 0.070 |
Why?
|
Terminal Care | 1 | 2020 | 1773 | 0.070 |
Why?
|
Mice, Nude | 3 | 2018 | 3635 | 0.070 |
Why?
|
Gene Expression Regulation, Neoplastic | 4 | 2020 | 8636 | 0.070 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 1 | 2022 | 3246 | 0.070 |
Why?
|
Drug Resistance | 1 | 2013 | 1599 | 0.070 |
Why?
|
Skin | 1 | 2021 | 4520 | 0.070 |
Why?
|
Platelet Adhesiveness | 1 | 2007 | 154 | 0.070 |
Why?
|
Tumor Burden | 3 | 2018 | 1909 | 0.070 |
Why?
|
Enzyme Inhibitors | 1 | 2017 | 3734 | 0.070 |
Why?
|
Cohort Studies | 4 | 2022 | 41782 | 0.060 |
Why?
|
Autoimmune Diseases | 1 | 2018 | 2260 | 0.060 |
Why?
|
Tumor Cells, Cultured | 3 | 2020 | 6135 | 0.060 |
Why?
|
Tissue Distribution | 2 | 2020 | 2298 | 0.060 |
Why?
|
Mass Screening | 1 | 2021 | 5455 | 0.060 |
Why?
|
Ovarian Neoplasms | 1 | 2022 | 4906 | 0.060 |
Why?
|
Logistic Models | 1 | 2020 | 13323 | 0.060 |
Why?
|
Models, Economic | 2 | 2019 | 717 | 0.060 |
Why?
|
Liver Neoplasms | 2 | 2018 | 4362 | 0.060 |
Why?
|
Ventricular Myosins | 1 | 2024 | 65 | 0.060 |
Why?
|
Troponin T | 2 | 2024 | 787 | 0.060 |
Why?
|
Thrombin | 1 | 2007 | 601 | 0.060 |
Why?
|
Cell Lineage | 2 | 2024 | 2575 | 0.060 |
Why?
|
MutS Homolog 2 Protein | 1 | 2024 | 200 | 0.060 |
Why?
|
MAP Kinase Kinase 1 | 2 | 2017 | 333 | 0.060 |
Why?
|
Electrocardiography | 2 | 2018 | 6410 | 0.060 |
Why?
|
Body Mass Index | 1 | 2021 | 13030 | 0.060 |
Why?
|
Cell Cycle Proteins | 1 | 2015 | 3464 | 0.060 |
Why?
|
Hypesthesia | 1 | 2024 | 106 | 0.050 |
Why?
|
Kaplan-Meier Estimate | 4 | 2018 | 6537 | 0.050 |
Why?
|
DNA | 1 | 2017 | 7213 | 0.050 |
Why?
|
von Willebrand Factor | 1 | 2007 | 679 | 0.050 |
Why?
|
Arthritis, Rheumatoid | 1 | 2018 | 3762 | 0.050 |
Why?
|
Nitric Oxide Synthase Type II | 1 | 2024 | 518 | 0.050 |
Why?
|
Signal Transduction | 2 | 2016 | 23639 | 0.050 |
Why?
|
Drug Screening Assays, Antitumor | 2 | 2016 | 720 | 0.050 |
Why?
|
Enzyme Activation | 3 | 2016 | 3594 | 0.050 |
Why?
|
Helicobacter pylori | 1 | 2006 | 382 | 0.050 |
Why?
|
Lasers | 1 | 2007 | 952 | 0.050 |
Why?
|
Helicobacter Infections | 1 | 2006 | 392 | 0.050 |
Why?
|
Lactates | 1 | 2023 | 401 | 0.050 |
Why?
|
B-Lymphocytes | 2 | 2024 | 4779 | 0.050 |
Why?
|
Quality-Adjusted Life Years | 2 | 2019 | 1734 | 0.050 |
Why?
|
United States | 6 | 2021 | 73120 | 0.050 |
Why?
|
Age Factors | 1 | 2018 | 18477 | 0.050 |
Why?
|
Cost-Benefit Analysis | 3 | 2019 | 5532 | 0.050 |
Why?
|
Fatal Outcome | 2 | 2018 | 1841 | 0.050 |
Why?
|
Ambulatory Care | 1 | 2012 | 2780 | 0.050 |
Why?
|
Mice, SCID | 2 | 2018 | 2633 | 0.050 |
Why?
|
Drug Therapy, Combination | 2 | 2023 | 6320 | 0.050 |
Why?
|
Dose-Response Relationship, Drug | 3 | 2020 | 10784 | 0.050 |
Why?
|
Disease Models, Animal | 5 | 2023 | 18390 | 0.040 |
Why?
|
Radiography, Thoracic | 2 | 2018 | 1320 | 0.040 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2024 | 876 | 0.040 |
Why?
|
Autoantigens | 1 | 2024 | 893 | 0.040 |
Why?
|
Troponin I | 1 | 2024 | 662 | 0.040 |
Why?
|
Genes, Tumor Suppressor | 1 | 2024 | 1064 | 0.040 |
Why?
|
Censuses | 1 | 2021 | 198 | 0.040 |
Why?
|
Iodine Radioisotopes | 1 | 2024 | 1035 | 0.040 |
Why?
|
Proteomics | 2 | 2024 | 3901 | 0.040 |
Why?
|
Lymphocyte Depletion | 1 | 2022 | 605 | 0.040 |
Why?
|
Transaminases | 1 | 2020 | 199 | 0.040 |
Why?
|
Immunoglobulin Fc Fragments | 1 | 2021 | 285 | 0.040 |
Why?
|
Chemokines | 1 | 2024 | 963 | 0.040 |
Why?
|
Phthalazines | 1 | 2022 | 396 | 0.040 |
Why?
|
Microscopy | 1 | 2024 | 909 | 0.040 |
Why?
|
Intention to Treat Analysis | 1 | 2020 | 417 | 0.040 |
Why?
|
Immunization, Secondary | 1 | 2022 | 371 | 0.040 |
Why?
|
Adaptive Immunity | 1 | 2024 | 734 | 0.040 |
Why?
|
Genomic Instability | 1 | 2023 | 714 | 0.040 |
Why?
|
Diphenylamine | 1 | 2018 | 49 | 0.040 |
Why?
|
Spirometry | 1 | 2022 | 928 | 0.040 |
Why?
|
Solvents | 1 | 2020 | 298 | 0.040 |
Why?
|
Heart | 2 | 2024 | 4451 | 0.040 |
Why?
|
Colorectal Neoplasms | 1 | 2018 | 6979 | 0.040 |
Why?
|
DNA Breaks, Double-Stranded | 1 | 2023 | 614 | 0.040 |
Why?
|
Ethylnitrosourea | 1 | 2018 | 50 | 0.040 |
Why?
|
Keratin-8 | 1 | 2017 | 11 | 0.040 |
Why?
|
Diagnosis, Differential | 3 | 2021 | 13025 | 0.040 |
Why?
|
Azetidines | 1 | 2019 | 143 | 0.040 |
Why?
|
Physical Exertion | 1 | 2021 | 669 | 0.040 |
Why?
|
Keratin-18 | 1 | 2017 | 37 | 0.040 |
Why?
|
Lymphatic Metastasis | 2 | 2016 | 2930 | 0.040 |
Why?
|
New York City | 1 | 2020 | 738 | 0.040 |
Why?
|
Antigens, Viral | 1 | 2022 | 992 | 0.040 |
Why?
|
Hyperplasia | 1 | 2021 | 1154 | 0.040 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 2024 | 1786 | 0.040 |
Why?
|
DNA Helicases | 1 | 2023 | 853 | 0.040 |
Why?
|
Albumins | 1 | 2020 | 578 | 0.040 |
Why?
|
Cyclin-Dependent Kinase 4 | 1 | 2021 | 564 | 0.040 |
Why?
|
Reference Standards | 1 | 2021 | 1015 | 0.040 |
Why?
|
Organoplatinum Compounds | 1 | 2018 | 408 | 0.030 |
Why?
|
Oncogene Fusion | 1 | 2017 | 83 | 0.030 |
Why?
|
Leucovorin | 1 | 2018 | 643 | 0.030 |
Why?
|
Mice, Knockout | 2 | 2024 | 14483 | 0.030 |
Why?
|
Confusion | 1 | 2018 | 278 | 0.030 |
Why?
|
Genes, erbB-2 | 1 | 2017 | 162 | 0.030 |
Why?
|
Immunocompromised Host | 1 | 2022 | 865 | 0.030 |
Why?
|
Blood Platelets | 1 | 2007 | 2485 | 0.030 |
Why?
|
Protein Conformation | 2 | 2014 | 3972 | 0.030 |
Why?
|
Genetic Engineering | 1 | 2022 | 936 | 0.030 |
Why?
|
Thrombophilia | 1 | 2018 | 306 | 0.030 |
Why?
|
Mendelian Randomization Analysis | 1 | 2021 | 1036 | 0.030 |
Why?
|
Antigen Presentation | 1 | 2021 | 1247 | 0.030 |
Why?
|
DNA Mismatch Repair | 1 | 2018 | 433 | 0.030 |
Why?
|
Extracellular Signal-Regulated MAP Kinases | 1 | 2018 | 617 | 0.030 |
Why?
|
Markov Chains | 1 | 2019 | 977 | 0.030 |
Why?
|
Esophagus | 1 | 2021 | 1045 | 0.030 |
Why?
|
Peripartum Period | 1 | 2016 | 138 | 0.030 |
Why?
|
Microsatellite Instability | 1 | 2018 | 726 | 0.030 |
Why?
|
Thorax | 1 | 2018 | 559 | 0.030 |
Why?
|
Tissue Array Analysis | 1 | 2016 | 551 | 0.030 |
Why?
|
Ligands | 1 | 2021 | 3279 | 0.030 |
Why?
|
Radiotherapy, Conformal | 1 | 2018 | 549 | 0.030 |
Why?
|
Proto-Oncogene Proteins pp60(c-src) | 1 | 2014 | 147 | 0.030 |
Why?
|
Family Characteristics | 1 | 2019 | 1001 | 0.030 |
Why?
|
Mutant Proteins | 1 | 2016 | 489 | 0.030 |
Why?
|
Tumor Suppressor Proteins | 1 | 2024 | 2819 | 0.030 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2014 | 109 | 0.030 |
Why?
|
Radiotherapy Dosage | 1 | 2021 | 2925 | 0.030 |
Why?
|
Fibroblasts | 1 | 2024 | 4180 | 0.030 |
Why?
|
T-Lymphocyte Subsets | 1 | 2022 | 1813 | 0.030 |
Why?
|
Benzoquinones | 1 | 2014 | 198 | 0.030 |
Why?
|
Feedback, Physiological | 1 | 2016 | 480 | 0.030 |
Why?
|
Inhibitory Concentration 50 | 1 | 2014 | 467 | 0.030 |
Why?
|
NIH 3T3 Cells | 1 | 2015 | 669 | 0.030 |
Why?
|
Liver Failure | 1 | 2015 | 252 | 0.030 |
Why?
|
Fluorouracil | 1 | 2018 | 1656 | 0.030 |
Why?
|
Fluorescent Antibody Technique | 1 | 2017 | 2477 | 0.030 |
Why?
|
Dendritic Cells | 1 | 2024 | 2753 | 0.030 |
Why?
|
Echocardiography | 2 | 2018 | 5043 | 0.030 |
Why?
|
Consensus | 1 | 2023 | 3207 | 0.030 |
Why?
|
Cytoskeletal Proteins | 1 | 2018 | 1337 | 0.030 |
Why?
|
Anticonvulsants | 1 | 2022 | 1923 | 0.030 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2018 | 1794 | 0.030 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2017 | 906 | 0.030 |
Why?
|
Internationality | 1 | 2017 | 1007 | 0.020 |
Why?
|
High-Throughput Screening Assays | 1 | 2017 | 939 | 0.020 |
Why?
|
Immunity, Innate | 1 | 2024 | 3076 | 0.020 |
Why?
|
Transfection | 1 | 2020 | 5767 | 0.020 |
Why?
|
Brain | 1 | 2018 | 27439 | 0.020 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2020 | 3550 | 0.020 |
Why?
|
Risk Assessment | 3 | 2021 | 24310 | 0.020 |
Why?
|
Molecular Structure | 1 | 2015 | 1889 | 0.020 |
Why?
|
Gene Knockdown Techniques | 1 | 2015 | 1609 | 0.020 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2021 | 2882 | 0.020 |
Why?
|
Fever | 1 | 2018 | 1622 | 0.020 |
Why?
|
Pharyngitis | 1 | 2012 | 222 | 0.020 |
Why?
|
Cell Death | 1 | 2016 | 1684 | 0.020 |
Why?
|
Societies, Medical | 1 | 2023 | 3954 | 0.020 |
Why?
|
Creatine Kinase | 1 | 2012 | 685 | 0.020 |
Why?
|
Streptococcus pyogenes | 1 | 2012 | 293 | 0.020 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2011 | 330 | 0.020 |
Why?
|
Mice, Inbred C57BL | 2 | 2024 | 22365 | 0.020 |
Why?
|
Inpatients | 1 | 2021 | 2561 | 0.020 |
Why?
|
MAP Kinase Signaling System | 1 | 2016 | 1489 | 0.020 |
Why?
|
Mice, Inbred BALB C | 1 | 2018 | 6241 | 0.020 |
Why?
|
Decision Support Techniques | 1 | 2019 | 2010 | 0.020 |
Why?
|
RNA, Small Interfering | 1 | 2018 | 3436 | 0.020 |
Why?
|
Sulfonamides | 1 | 2018 | 1988 | 0.020 |
Why?
|
Massachusetts | 1 | 2021 | 8905 | 0.020 |
Why?
|
Disease Management | 1 | 2019 | 2533 | 0.020 |
Why?
|
Macrophages | 1 | 2023 | 5797 | 0.020 |
Why?
|
Lymphocyte Activation | 1 | 2019 | 5490 | 0.020 |
Why?
|
Nuclear Proteins | 1 | 2023 | 5808 | 0.020 |
Why?
|
Adolescent | 3 | 2022 | 89163 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2017 | 2465 | 0.020 |
Why?
|
Australia | 1 | 2011 | 1264 | 0.020 |
Why?
|
Diagnostic Imaging | 1 | 2022 | 3543 | 0.020 |
Why?
|
Fura-2 | 1 | 2007 | 107 | 0.020 |
Why?
|
Boston | 1 | 2020 | 9359 | 0.020 |
Why?
|
Binding Sites | 1 | 2015 | 6029 | 0.020 |
Why?
|
Weight Loss | 1 | 2018 | 2710 | 0.020 |
Why?
|
Proto-Oncogene Proteins B-raf | 1 | 2017 | 2072 | 0.020 |
Why?
|
Recurrence | 1 | 2019 | 8510 | 0.020 |
Why?
|
Case-Control Studies | 1 | 2024 | 22286 | 0.020 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2011 | 614 | 0.020 |
Why?
|
Gene Expression Profiling | 1 | 2022 | 9508 | 0.020 |
Why?
|
Multicenter Studies as Topic | 1 | 2011 | 1727 | 0.020 |
Why?
|
Caspase 9 | 1 | 2006 | 185 | 0.020 |
Why?
|
Diagnostic Tests, Routine | 1 | 2011 | 792 | 0.020 |
Why?
|
Cell Growth Processes | 1 | 2006 | 383 | 0.020 |
Why?
|
Chest Pain | 1 | 2012 | 1099 | 0.020 |
Why?
|
Magnetic Resonance Imaging, Cine | 1 | 2012 | 1092 | 0.020 |
Why?
|
Phosphorylation | 1 | 2016 | 8331 | 0.020 |
Why?
|
Mitochondrial Membranes | 1 | 2006 | 185 | 0.020 |
Why?
|
Gene Expression | 1 | 2017 | 7605 | 0.020 |
Why?
|
Phenotype | 1 | 2023 | 16712 | 0.010 |
Why?
|
Cell Differentiation | 1 | 2022 | 11674 | 0.010 |
Why?
|
Colonic Neoplasms | 1 | 2016 | 2544 | 0.010 |
Why?
|
Caspase 3 | 1 | 2006 | 732 | 0.010 |
Why?
|
Platelet Activation | 1 | 2007 | 646 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2021 | 7449 | 0.010 |
Why?
|
Gastric Mucosa | 1 | 2006 | 603 | 0.010 |
Why?
|
Caspases | 1 | 2006 | 884 | 0.010 |
Why?
|
Immunoglobulin G | 1 | 2015 | 4570 | 0.010 |
Why?
|
Transcription Factors | 1 | 2023 | 12176 | 0.010 |
Why?
|
Membrane Potentials | 1 | 2006 | 1090 | 0.010 |
Why?
|
Pilot Projects | 1 | 2016 | 8730 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2024 | 26348 | 0.010 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2019 | 9066 | 0.010 |
Why?
|
Calcium Signaling | 1 | 2007 | 737 | 0.010 |
Why?
|
Medicare | 1 | 2020 | 6880 | 0.010 |
Why?
|
Incidence | 1 | 2020 | 21552 | 0.010 |
Why?
|
Pandemics | 1 | 2021 | 8751 | 0.010 |
Why?
|
Coronary Angiography | 1 | 2012 | 4526 | 0.010 |
Why?
|
Hypertension | 1 | 2020 | 8610 | 0.010 |
Why?
|
Spleen | 1 | 2006 | 2298 | 0.010 |
Why?
|
Risk Factors | 2 | 2021 | 74915 | 0.010 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2006 | 1409 | 0.010 |
Why?
|
Kinetics | 1 | 2007 | 6347 | 0.010 |
Why?
|
Smoking | 1 | 2016 | 9099 | 0.010 |
Why?
|
Fluorescent Dyes | 1 | 2007 | 1924 | 0.010 |
Why?
|
Pancreatic Neoplasms | 1 | 2016 | 5443 | 0.010 |
Why?
|
Quality of Life | 1 | 2019 | 13497 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2011 | 12561 | 0.010 |
Why?
|
Pregnancy | 1 | 2016 | 30179 | 0.010 |
Why?
|
Calcium | 1 | 2007 | 5793 | 0.010 |
Why?
|
Thrombosis | 1 | 2007 | 2954 | 0.010 |
Why?
|
Myocardial Infarction | 1 | 2012 | 11515 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2018 | 36840 | 0.010 |
Why?
|